Releases
IKT
1.760
+1.15%
0.020
  • All
  • Financials
  • Insiders
More
Webull provides the latest Inhibikase Therapeutics Inc (IKT) stock and general news. This information may help you make smarter investment decisions.
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).